R-Zero has recently announced new investment from Mayo Clinic in the development and advancement of its automated disinfection ecosystem. In addition, the two companies have entered into a strategic, co-development partnership to advance the practice of creating healthy building systems moving forward.
“Solving the world’s toughest problems requires bringing together the world’s smartest minds and leading experts. Today, as we work to solve one of the most important human health challenges, we are humbled and proud to have the backing of Mayo Clinic and are incredibly excited to collaborate with an elite medical institution with a tremendous track record for innovation and excellence,” said Grant Morgan, Co-Founder and CEO of R-Zero.
“In collaboration with the world-leading experts at Mayo Clinic, we have the opportunity to create novel technologies that fundamentally change the way we keep humans safe in indoor spaces – from hospitals, to schools, to the workplace and all of the shared spaces where we as humans spend 90% of our lives.”
Mayo Will Help Co-Develop R-Zero’s Next-Gen Biosafety Platform
Today, R-Zero is emerging as a world leader in delivering innovative biosafety technologies to address glaring gaps in society’s health protections against COVID-19, a set of hospital acquired infections and all other common infectious diseases within indoor spaces.
As part of this collaboration, Mayo Clinic will also provide its exceptional subject matter expertise in infection disease and hospital safety to help co-develop R-Zero’s next-generation biosafety technology platform. The goal is to be able to leverage leading evidence-based medicine expertise in clinical trials, while also creating an integrated data management platform rooted in novel AI-based algorithms and software to create a safe, efficient technology solution for disinfecting indoor spaces.
“R-Zero is a highly differentiated company that is using realtime data and artificial intelligence to deliver a multitude of interventions that would provide a healthier indoor environment”, says Elie Berbari, M.D., chair, Division of Infectious Diseases at Mayo Clinic and one of the lead investigators in this engagement. “Mayo Clinic’s collaboration and investment in this technology will deliver a set of technologic substitutions to current solutions that may disrupt existing models aimed at delivering a safe indoor environment.”
